Overview

Hazardous drug therapies such as oncology medications can pose significant risks to patients and healthcare providers during medication preparation and administration 1,2

A 2018 IV chemotherapy compounding pan-Canadian study revealed the potential for 11 types of latent errors to occur in pharmacies that could lead to patient harm or death 1

Furthermore, According to CAREX Canada, over 75,000 Canadian health care workers are occupationally exposed to antineoplastic (hazardous) drugs. Prolonged exposure to hazardous drugs can lead to irreversible adverse effects such as cancer, organ damage, reproductive problems 2, 3

 

Best practices

BD advocates for the adoption of best practices to address oncology medication safety for patients and providers

The Canadian National Association of Pharmacy Regulatory Authorities (NAPRA) 2016 Standards support the use of closed system transfer devices to protect health care workers from exposure, and the use of electronic workflow systems to document preparations4.

The Institute for Safe Medication Practices supports the use of IV compounding workflow systems that employ barcoding and gravimetric techniques to reduce the risk for errors5.

The Infusion Nurses Society supports the practice of standardizing infusion pumps, when feasible, to promote user familiarity with operation6.

BD Technologies

How BD Technologies can help

BD’s technologies help to standardize and streamline the oncology medication use process, from preparation through administration and documentation, improving medication safety for patients, while protecting healthcare workers from hazardous drug exposure throughout the enterprise.

Learn More

Partner with BD

Ready to imagine how an entire connected ecosystem can improve outcomes across your organization? 

We want to speak with you.

Talk to our solutions experts

References
  1. Gilbert RE, Kozak MC, Dobish RB, Bourrier VC, Koke PM, Kukreti V, Logan HA, Easty AC, Trbovich PL. Intravenous Chemotherapy Compounding Errors in a Follow-Up Pan-Canadian Observational Study. Journal of oncology practice. 2018 Apr 20;14(5):e295303.
  2. McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010;52(10):1028-1034.
  3. Carex Canada 2018, Antineoplastic Agents, Occupational Estimate, https://www.carexcanada.ca/en/antineoplastic_agents/occupational_estimate/
  4. The Canadian National Association of Pharmacy Regulatory Authorities. Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations. 2016.
  5. Institute for Safe Medication Practices. ISMP Guidelines for Safe Preparation of Compounded Sterile Preparations. 2016.
  6. Institute for Safe Medication Practices. ISMP Guidelines for Safe Preparation of Compounded Sterile Preparations. 2016.
  7. Gorski L, Hadaway L, Hagle M, Friedman M, Orr M, Doellman D. Infusion Therapy Standards of Practice. 2016.
  8. Roberts PA, Willoughby IR, Barnes N, Eckel SF, Paruscio A, Valgus JM, Amerine LB. Evaluation of a gravimetric-based technology-assisted workflow system on hazardous sterile product preparation. American Journal of Health-System Pharmacy. 2018 Sep 1;75(17):1286-92.
  9. Reece KM, Lozano MA, Roux R, Spivey SM. Implementation and evaluation of a gravimetric iv workflow software system in an oncology ambulatory care pharmacy. American Journal of Health-System Pharmacy. 2016;73(3):165-73.
  10. Alaris™ EMR interoperability case study. Helping improve infusion-medication safety and documentation. St. Vincent Healthcare (SVH). 2018. Available at: https://www.bd.com/documents/case-studies/infusion/IF_Alaris-EMR-Interop-St-Vincent_CS_EN.pdf
  11. Simon N, Vasseur M, Pinturaud M, et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study. PLoS ONE. 2016;11(7):e0159052. doi: 10.1371/journal.pone.0159052.
  12. Sessink PJM, Trahan J, Coyne JW. Reduction in Surface Contamination with Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device. Hosp Pharm. 2013;48(3):204-212. doi: 10.1310/hpj4803-204.